 |
|
|
 |
|
Rationale:
- In most persons, hepatitis A resolves without complications or sequelae; however, some patients may experience complications,
including relapsing hepatitis A, cholestatic hepatitis A, or fulminant hepatitis A.
- Infection with HAV appears to confer life-long immunity.
|
|
Evidence:
|
|
Comments:
- No consensus exists regarding the frequency with which patients with uncomplicated hepatitis A should be monitored for clinical
and laboratory improvement.
- Reinnoculation with HAV failed to induce disease in experimentally infected persons (71; 108).
- Subsequent attacks of hepatitis A after initial infection have not been documented.
|
| FAQs |
|
|
|
Brian J. McMahon, MD, MACP has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Catherine M. Dentinger, FNP, MS has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
|
|
|
|
The information included herein should never be used as a substitute
for clinical judgment and does not represent an official position of
ACP. Because all PIER modules are updated regularly, printed web pages
or PDFs may rapidly become obsolete. Therefore, PIER users should
compare the date of the last update on the website with any printout
to ensure that the information being referred to is the most current
available.
|
PIER is copyrighted (c) 2008 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.
|
|
|
Hepatitis A
> Follow-up
